Decoy Therapeutics Inc.
DCOY
$2.99
$0.010.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.51% | 281.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.21% | 342.06% | |||
| Operating Income | -5.24% | -342.06% | |||
| Income Before Tax | -6.71% | 75.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.71% | 75.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.71% | 75.22% | |||
| EBIT | -5.24% | -342.06% | |||
| EBITDA | -4.92% | -344.19% | |||
| EPS Basic | -6.71% | 82.17% | |||
| Normalized Basic EPS | -6.70% | -248.17% | |||
| EPS Diluted | -6.71% | 82.17% | |||
| Normalized Diluted EPS | -6.70% | -248.17% | |||
| Average Basic Shares Outstanding | 0.00% | 39.01% | |||
| Average Diluted Shares Outstanding | 0.00% | 39.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||